| SOLVAY PHARMACEUTICALS B.V. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110086844 | Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance - An immediate release pharmaceutical formulation of a poorly water-soluble biologically active substance with enhanced bio-availability, the formulation being a homogeneous and thermostable solid solution, and the solid solution including as percentages of the total weight of the formulation:
| 04-14-2011 |
| 20110003830 | PROCESS FOR THE PREPARATION OF 3-AMINO-8-(1-PIPERAZINYL)-2H-1-BENZOPYRAN-2-ONE AND SALTS AND SOLVATES THEREOF - The invention relates to a novel process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one, a broad spectrum 5-HT receptor binding ligand having potent 5-HT | 01-06-2011 |
| 20100292248 | COMBINATION PREPARATIONS COMPRISING SLV308 AND A DOPAMINE AGONIST - A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: | 11-18-2010 |
| 20100249106 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds - Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme. | 09-30-2010 |
| 20100010062 | METHOD OF TREATMENT USING EPROSARTAN - The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg. | 01-14-2010 |
